Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical composition containing monosialotetrahexosyl ganglioside sodium and application thereof

A technology of sodium ganglioside and monosialic acid, applied in the field of medicine, can solve the problem that the repair rate of pheochromocytoma cells needs to be improved, and achieve the effects of promoting brain nerve metabolism, good quality of extract and better cost

Active Publication Date: 2022-04-05
BEIJING SIHUAN PHARMA +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The cell repair rate of existing drugs for pheochromocytoma needs to be improved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing monosialotetrahexosyl ganglioside sodium and application thereof
  • Pharmaceutical composition containing monosialotetrahexosyl ganglioside sodium and application thereof
  • Pharmaceutical composition containing monosialotetrahexosyl ganglioside sodium and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] Example 1 Preparation of the pharmaceutical composition containing monosialotetrahexosyl ganglioside sodium of the present invention

[0070] The preparation of the pharmaceutical composition containing monosialotetrahexosyl ganglioside sodium of the present invention comprises the following steps:

[0071] (1) Mince 10kg of pretreated rabbit muscle until the volume is not higher than 1cm 3 After mixing the obtained minced muscle with water for injection at a ratio of 1:2 (w / w), homogenate, place the obtained muscle homogenate below -10°C and freeze it for 6 days, and then place it in Melt at 9°C for 40 hours, then heat the melted rabbit muscle homogenate to 75°C, keep it warm for 20 minutes, then cool it down to room temperature, and centrifuge to obtain a filtrate;

[0072] (2) Adjust the pH of the filtrate once to 2.5, heat it to 37°C, add 0.1% pepsin, keep it at 37°C for enzymolysis for 2 hours, then adjust the pH of the liquid to 8, heat it at 75°C for 20 minute...

Embodiment 2

[0079] Example 2 Preparation of the pharmaceutical composition containing monosialotetrahexosyl ganglioside sodium of the present invention

[0080] The preparation of the pharmaceutical composition containing monosialotetrahexosyl ganglioside sodium of the present invention comprises the following steps:

[0081] (1) Mince 10kg of pretreated rabbit muscle until the volume is ≤1cm 3 After mixing the obtained minced muscle with water for injection at a ratio of 1:1 (w / w), homogenate, place the obtained muscle homogenate below -10°C and freeze it for 5 days, and then place it in Melt at 8°C for 36 hours, then heat the melted rabbit muscle homogenate to 70°C, keep it warm for 15 minutes, then cool it down to room temperature, and centrifuge to obtain a filtrate;

[0082] (2) Adjust the pH of the filtrate once to 2.0, heat it to 35°C, add 0.05% pepsin, keep it at 35°C for 0.5 hours, then adjust the pH of the liquid to 7.5, heat it at 70°C for 15 minutes, and cool down to 35°C,...

Embodiment 3

[0089] Example 3 Preparation of the pharmaceutical composition containing monosialotetrahexosyl ganglioside sodium of the present invention

[0090] The preparation of the pharmaceutical composition containing monosialotetrahexosyl ganglioside sodium of the present invention comprises the following steps:

[0091] (1) Mince 10kg of pretreated rabbit muscle until the volume is not higher than 1cm 3 After mixing the obtained minced muscle with water for injection at a ratio of 1:3 (w / w), homogenate, place the obtained muscle homogenate below -10°C and freeze it for 7 days, then place it in Melt at 10°C for 48 hours, then heat the melted rabbit muscle homogenate to 80°C, keep it warm for 25 minutes, then cool it down to room temperature, and centrifuge to obtain a filtrate;

[0092] (2) Adjust the pH of the filtrate once to 3.0, heat it to 40°C, add 0.5% pepsin, keep it at 40°C for enzymolysis for 3 hours, then adjust the pH of the liquid to 8.5, heat it at 80°C for 30 minutes...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention relates to a pharmaceutical composition containing monosialotetrahexosyl ganglioside sodium, the active ingredients of the composition comprise 0.1-1% (w / w) of monosialotetrahexosyl ganglioside sodium and a rabbit meat extract containing compound amino acid with the concentration of 1-20 mg / ml, the pH value of the composition is 6-8, and the content of the compound amino acid is 1-20 mg / ml. The mass ratio of the monosialotetrahexosyl ganglioside sodium to the compound amino acid in the composition is 1: (1-10). The pharmaceutical composition disclosed by the invention has the beneficial effects of reducing the volume of encephaledema, improving ischemia and hypoxia conditions of a central nervous system, repairing and protecting nerves, remarkably improving the repair rate of pheochromocytoma damaged cells and the like.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition containing monosialotetrahexosyl ganglioside sodium, a preparation method thereof and an application thereof. Background technique [0002] Monosialotetrahexosyl ganglioside (GM1) maintains Na+-K+-ATPase and Ca 2+ -Mg2+-ATPase activity to maintain the balance of intracellular and intracellular ions, reduce nerve cell edema, and prevent intracellular Ca 2+ Accumulation, used to resist the neurotoxic effect of excitatory amino acids, reduce the damage of free radicals to nerve cells, etc., and can promote nerve remodeling and functional recovery after central nervous system damage caused by various reasons. Central nervous system injury, Parkinson's disease and other diseases have good curative effect, clinically used to treat central nervous system lesions caused by various reasons. [0003] Pheochromocytoma (PA) mostly occurs in the adr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/34A61P9/10A61P9/14A61P25/00A61P25/02A61P25/16A61P25/28A61P27/02A61P31/14A61K31/198A61K31/401A61K31/4172A61K31/7032
Inventor 王建辉杨阳杨玉辉赵友明
Owner BEIJING SIHUAN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com